Cargando…

Ethyl Pyruvate Stimulates Regulatory T Cells and Ameliorates Type 1 Diabetes Development in Mice

Type 1 diabetes (T1D) is an autoimmune disease in which a strong inflammatory response causes the death of insulin-producing pancreatic β-cells, while inefficient regulatory mechanisms allow that response to become chronic. Ethyl pyruvate (EP), a stable pyruvate derivate and certified inhibitor of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Koprivica, Ivan, Vujičić, Milica, Gajić, Dragica, Saksida, Tamara, Stojanović, Ivana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335294/
https://www.ncbi.nlm.nih.gov/pubmed/30687329
http://dx.doi.org/10.3389/fimmu.2018.03130
_version_ 1783387859153059840
author Koprivica, Ivan
Vujičić, Milica
Gajić, Dragica
Saksida, Tamara
Stojanović, Ivana
author_facet Koprivica, Ivan
Vujičić, Milica
Gajić, Dragica
Saksida, Tamara
Stojanović, Ivana
author_sort Koprivica, Ivan
collection PubMed
description Type 1 diabetes (T1D) is an autoimmune disease in which a strong inflammatory response causes the death of insulin-producing pancreatic β-cells, while inefficient regulatory mechanisms allow that response to become chronic. Ethyl pyruvate (EP), a stable pyruvate derivate and certified inhibitor of an alarmin–high mobility group box 1 (HMGB1), exerts anti-oxidant and anti-inflammatory properties in animal models of rheumatoid arthritis and encephalomyelitis. To test its therapeutic potential in T1D, EP was administered intraperitoneally to C57BL/6 mice with multiple low-dose streptozotocin (MLDS)-induced T1D. EP treatment decreased T1D incidence, reduced the infiltration of cells into the pancreatic islets and preserved β-cell function. Apart from reducing HMGB1 expression, EP treatment successfully interfered with the inflammatory response within the local pancreatic lymph nodes and in the pancreas. Its effect was restricted to boosting the regulatory arm of the immune response through up-regulation of tolerogenic dendritic cells (CD11c(+)CD11b(−)CD103(+)) within the pancreatic infiltrates and through the enhancement of regulatory T cell (Treg) levels (CD4(+)CD25(high)FoxP3(+)). These EP-stimulated Treg displayed enhanced suppressive capacity reflected in increased levels of CTLA-4, secreted TGF-β, and IL-10 and in the more efficient inhibition of effector T cell proliferation compared to Treg from diabetic animals. Higher levels of Treg were a result of increased differentiation and proliferation (Ki67(+) cells), but also of the heightened potency for migration due to increased expression of adhesion molecules (CD11a and CD62L) and CXCR3 chemokine receptor. Treg isolated from EP-treated mice had the activated phenotype and T-bet expression more frequently, suggesting that they readily suppressed IFN-γ-producing cells. The effect of EP on Treg was also reproduced in vitro. Overall, our results show that EP treatment reduced T1D incidence in C57BL/6 mice predominantly by enhancing Treg differentiation, proliferation, their suppressive capacity, and recruitment into the pancreas.
format Online
Article
Text
id pubmed-6335294
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63352942019-01-25 Ethyl Pyruvate Stimulates Regulatory T Cells and Ameliorates Type 1 Diabetes Development in Mice Koprivica, Ivan Vujičić, Milica Gajić, Dragica Saksida, Tamara Stojanović, Ivana Front Immunol Immunology Type 1 diabetes (T1D) is an autoimmune disease in which a strong inflammatory response causes the death of insulin-producing pancreatic β-cells, while inefficient regulatory mechanisms allow that response to become chronic. Ethyl pyruvate (EP), a stable pyruvate derivate and certified inhibitor of an alarmin–high mobility group box 1 (HMGB1), exerts anti-oxidant and anti-inflammatory properties in animal models of rheumatoid arthritis and encephalomyelitis. To test its therapeutic potential in T1D, EP was administered intraperitoneally to C57BL/6 mice with multiple low-dose streptozotocin (MLDS)-induced T1D. EP treatment decreased T1D incidence, reduced the infiltration of cells into the pancreatic islets and preserved β-cell function. Apart from reducing HMGB1 expression, EP treatment successfully interfered with the inflammatory response within the local pancreatic lymph nodes and in the pancreas. Its effect was restricted to boosting the regulatory arm of the immune response through up-regulation of tolerogenic dendritic cells (CD11c(+)CD11b(−)CD103(+)) within the pancreatic infiltrates and through the enhancement of regulatory T cell (Treg) levels (CD4(+)CD25(high)FoxP3(+)). These EP-stimulated Treg displayed enhanced suppressive capacity reflected in increased levels of CTLA-4, secreted TGF-β, and IL-10 and in the more efficient inhibition of effector T cell proliferation compared to Treg from diabetic animals. Higher levels of Treg were a result of increased differentiation and proliferation (Ki67(+) cells), but also of the heightened potency for migration due to increased expression of adhesion molecules (CD11a and CD62L) and CXCR3 chemokine receptor. Treg isolated from EP-treated mice had the activated phenotype and T-bet expression more frequently, suggesting that they readily suppressed IFN-γ-producing cells. The effect of EP on Treg was also reproduced in vitro. Overall, our results show that EP treatment reduced T1D incidence in C57BL/6 mice predominantly by enhancing Treg differentiation, proliferation, their suppressive capacity, and recruitment into the pancreas. Frontiers Media S.A. 2019-01-10 /pmc/articles/PMC6335294/ /pubmed/30687329 http://dx.doi.org/10.3389/fimmu.2018.03130 Text en Copyright © 2019 Koprivica, Vujičić, Gajić, Saksida and Stojanović. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Koprivica, Ivan
Vujičić, Milica
Gajić, Dragica
Saksida, Tamara
Stojanović, Ivana
Ethyl Pyruvate Stimulates Regulatory T Cells and Ameliorates Type 1 Diabetes Development in Mice
title Ethyl Pyruvate Stimulates Regulatory T Cells and Ameliorates Type 1 Diabetes Development in Mice
title_full Ethyl Pyruvate Stimulates Regulatory T Cells and Ameliorates Type 1 Diabetes Development in Mice
title_fullStr Ethyl Pyruvate Stimulates Regulatory T Cells and Ameliorates Type 1 Diabetes Development in Mice
title_full_unstemmed Ethyl Pyruvate Stimulates Regulatory T Cells and Ameliorates Type 1 Diabetes Development in Mice
title_short Ethyl Pyruvate Stimulates Regulatory T Cells and Ameliorates Type 1 Diabetes Development in Mice
title_sort ethyl pyruvate stimulates regulatory t cells and ameliorates type 1 diabetes development in mice
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335294/
https://www.ncbi.nlm.nih.gov/pubmed/30687329
http://dx.doi.org/10.3389/fimmu.2018.03130
work_keys_str_mv AT koprivicaivan ethylpyruvatestimulatesregulatorytcellsandamelioratestype1diabetesdevelopmentinmice
AT vujicicmilica ethylpyruvatestimulatesregulatorytcellsandamelioratestype1diabetesdevelopmentinmice
AT gajicdragica ethylpyruvatestimulatesregulatorytcellsandamelioratestype1diabetesdevelopmentinmice
AT saksidatamara ethylpyruvatestimulatesregulatorytcellsandamelioratestype1diabetesdevelopmentinmice
AT stojanovicivana ethylpyruvatestimulatesregulatorytcellsandamelioratestype1diabetesdevelopmentinmice